HIV Infections
Conditions
Keywords
Simplification therapy, Efficacy, Safety, Virological effectiveness, Immunological effectiveness, HIV
Brief summary
To evaluate the therapeutic equivalence between the two arms of treatment in virological and immunological response after 48 weeks and to evaluate the presence of side effects during the follow-up period.
Detailed description
The efficacy of the highly active antiretroviral treatment (HAART) has been demonstrated in several clinical trials. Even so, a substantial proportion of patients do not manage to maintain correct viral suppression in daily clinical practice. Adherence to HAART treatment is critical to obtain lasting viral suppression. Thus, factors that are related to adherence such as high pill load or takes, the complexity of the antiretroviral system, tolerability and food restrictions may have an effect on viral replication. It has been demonstrated that simpler regimens with a scant number of tablets, without food restrictions and with a single take a day are safe, efficacious and that adherence improves. The combination of abacavir 600 mg + lamivudine 300 mg QD in a single tablet is a novel dosage that may help increase treatment adherence.
Interventions
DRUGKivexa
abacavir 600mg + lamivudine 300mg in one tablet QD
Sponsors
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Germans Trias i Pujol Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Age\> 18 years. 2. HIV-1 infected patients. 3. Naive to antiretroviral treatment. 4. Candidate patient for initiating antiretroviral treatment\*. 5. Subject able to follow the treatment period. 6. Signature of the informed consent. 7. Women may not be fertile age (defined as at least one year from menopause or undergoing any surgical sterilisation technique), or must undertake to use two contraceptive methods during the study, one of them at least being a barrier method.
Exclusion criteria
1. Hepatic tests \> 5 times above normality. 2. Pregnancy or breastfeeding. 3. Treatment for opportunistic infections or neoplasms associated with the stable HIV over the last 6 weeks. 4. Suspected or documented resistance to any of the investigational drugs. 5. Known allergic hypersensitivity to any of the investigational drugs or any similar drug. 6. Subjects with abusive consumption of alcohol or illegal drugs. 7. Patients participating in another clinical trial. 8. Terminal renal disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the virological response over the 48 weeks of the study. | At 12, 24, 36 and 48 weeks |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the immunological efficacy (changes in CD4 and CD8 counts) of the combination studied over the follow-up period. | At 12, 24, 36 and 48 weeks. |
| To evaluate the impact of treatment on the lipid profile. | At 12, 24, 36 and 48 weeks |
| To evaluate the tolerance and safety of the combination of Efavirenz + lamivudine + abacavir given once daily over the 48-week treatment period. | At 12, 24, 36 and 48 weeks. |
| To evaluate treatment adherence (assessed by a self-reported questionnaire and with graduated satisfaction scales) and patient quality of life (assessed by means of the MOS-HIV questionnaire). | At 12, 24, 36 and 48 weeks. |
| To analyse the mutations that appear in patients that present virological failure. | When there is a virological failure. |
Countries
Italy, Spain
Outcome results
None listed